Metabolic effects of troglitazone monotherapy in type 2 diabetes mellitus. A randomized, double-blind, placebo-controlled trial

Annals of Internal Medicine

Volumn 128, Issue 3, 1998, Pages 176-185

  Maggs, David G ^a   Buchanan, Thomas A ^b   Burant, Charles F ^c   Cline, Gary ^a   Gumbiner, Barry ^d   Hsueh, Willa A ^e   Inzucchi, Silvio ^a   Kelley, David ^f   Nolan, John ^g   Olefsky, Jerrold M ^h   Polonsky, Kenneth S ^c   Silver, David ^a   Valiquett, Thomas R ⁱ   Shulman, Gerald I ^a  

^a YALE UNIVERSITY SCHOOL OF MEDICINE   (United States)

^b UNIVERSITY OF SOUTHERN CALIFORNIA   (United States)

^c UNIVERSITY OF CHICAGO MEDICAL CENTER   (United States)

^d Natl Inst for Fitness and Sport   (United States)

^e UNIVERSITY OF SOUTHERN CALIFORNIA   (United States)

^f UNIVERSITY OF PITTSBURGH SCHOOL OF MEDICINE   (United States)

^g ST JAMES S HOSPITAL   (Ireland)

^h UNIVERSITY OF CALIFORNIA   (United States)

ⁱ PFIZER INC   (United States)

Author keywords

[No Author keywords available]

Indexed keywords

C PEPTIDE; PLACEBO; TROGLITAZONE;

ADULT; ARTICLE; BEHAVIOR MODIFICATION; CLINICAL TRIAL; CONTROLLED CLINICAL TRIAL; CONTROLLED STUDY; DOUBLE BLIND PROCEDURE; DRUG EFFECT; FEMALE; GLUCOSE ABSORPTION; GLUCOSE METABOLISM; HUMAN; INSULIN RELEASE; INSULIN RESISTANCE; INSULIN SENSITIVITY; MAJOR CLINICAL STUDY; MALE; METABOLIC REGULATION; NON INSULIN DEPENDENT DIABETES MELLITUS; PRIORITY JOURNAL; RANDOMIZED CONTROLLED TRIAL; REGRESSION ANALYSIS;

EID: 0032005178     PISSN: 00034819     EISSN: None     Source Type: Journal    
DOI: 10.7326/0003-4819-128-3-199802010-00002     Document Type: Article

References (38)

1. DeFronzo RA. Pathogenesis of type 2 (non-insulin dependent) diabetes mellitus: a balanced overview. Diabetologia. 1992;35:389-97.
2. Reaven G. Role of insulin resistance in the pathophysiology of non-insulin dependent diabetes mellitus. Diab Met Rev. 1993;9(Suppl 1):5-12.
3. Stumvoll M, Nurjhan N, Perriello G, Dailey G, Gerich JE. Metabolic effects of metformin in non-insulin-dependent diabetes mellitus. N Engl J Med. 1995;333:550-4.
4. Clissold S, Edwards C. Acarbose. A preliminary review of its pharmacodynamic and pharmacokinetic properties, and therapeutic potential. Drugs. 1988;35:214-43.
5. Fujiwara T, Yoshioka S, Yoshioka T, Ushiyama I, Horikoshi H. Characterization of a new and antidiabetic agent, CS-045. Studies in KK and ob/ob mice and Zucker fatty rats. Diabetes. 1988;37:1549-58.
6. Fujiwara T, Wade M, Fukuda K, Fukami M, Yoshioka S, Yoshioka T, et al. Characterization of CS-045, a new oral antidiabetic agent, II. Effects on glycemic control and pancreatic islet structure at a late stage of the diabetic syndrome in C57BL/KsJ-db/db mice. Metabolism. 1991;40:1213-8.
7. Suter SL, Nolan J, Wallace P, Gumbiner B, Olefsky JM. Metabolic effects of a new oral hypoglycemic agent CS-045 in NIDDM subjects. Diabetes Care. 1992;15:193-203.
8. Akanuma Y, Kosaka K, Kuzuka K, Shimizu N, Shigeta Y, Kaneko T. Long term study of a new oral hypoglycemic drug CS-045 in patients with non-insulin dependent diabetes mellitus. Rinsho Iyaka. 1993;9(Suppl 3):127-49.
9. Kosaka K, Kuzuka K, Akanuma Y, Shigeta Y, Kaneko T. Clinical evaluation of a new oral hypoglycemic drug CS-045 in patients with non-insulin dependent diabetes mellitus poorly controlled by diet alone: a double-blind, placebo-controlled study. J Clin Ther Med. 1993;9(Suppl 3):61-93.
10. Kosaka K, Kuzuka K, Akanuma Y, Shigeta Y, Kaneko T. Clinical evaluation of a new oral hypoglycemic drug CS-045 in patients with non-insulin dependent diabetes mellitus poorly controlled by sulphonylureas: a double-blind, placebo-controlled study. J Clin Ther Med. 1993;9(Suppl 3):95-126.
11. Iwamoto Y, Kosaka K, Kuzuya T, Akanuma Y, Shigeta Y. Kaneko T. Effect of combination therapy of troglitazone and sulphonylureas in patients with Type 2 diabetes who were poorly controlled by sulphonylurea therapy alone. Diabet Med. 1995;13:365-70.
12. Iwamoto I, Kosaka K, Kuzuya Y, Akanuma Y, Shigeta Y, Kaneko T. Effects of troglitazone: a new hypoglycemic agent in patients with NIDDM poorly controlled by diet therapy. Diabetes Care. 1996;19:151-6.
13. Kumar S, Boulton A, Beck-Nielsen H, Berthezene F, Muggeo M, Persson B, et al. Troglitazone, an insulin enhancer, improves metabolic control in NIDDM patients. Troglitazone Study Group. Diabetologia. 1996;39:701-9.
14. Classification and diagnosis of diabetes mellitus and other categories of glucose intolerance. National Diabetes Data Group. Diabetes. 1979;28:1039-57.
15. DeFronzo RA, Tobin JD, Andres R. Glucose clamp technique: a method for quantifying insulin secretion and resistance. Am J Physiol. 1979;237:E214-23.
16. Harris JA, Benedict FG. A Biometric Study of Basal Metabolism in Man. Washington, DC: Carnegie Institute of Washington; 1919. Publication no. 279.
17. Wolfe RR. Radioactive and Stable Isotope Tracers in Biomedicine. Principles and Practice of Kinetic Analysis. New York: Wiley-Liss; 1992:283-315.
18. Elbrecht A, Chen Y, Cullinan CA, Hayes N, Leibowitz MD, Moller DE, et al. Molecular cloning, expression and characterization of human peroxisome proliferator activated receptors gamma 1 and gamma 2. Biochem Biophys Res Commun. 1996;224:431-7.
19. Bader S, Kiehn R, Haring H. Effect of CS-045 on the activity of insulin receptor kinase in the skeletal muscle of insulin resistant Zucker rats. Diabetes und Stoffwechsel. 1993;2:56-61.
20. Kellerer M, Kroder G, Tippmer S, Berti L, Kiehn R, Mosthaf L, et al. Troglitazone prevents glucose-induced insulin resistance of insulin receptor in rat 1 fibroblasts. Diabetes. 1994;43:447-53.
21. Ciaraldi TP, Gilmore A, Olefsky JM, Goldberg M, Heidenreich KA. In vitro studies on the action of CS-045, a new antidiabetic agent. Metabolism. 1990;39:1056-62.
22. Randle P, Garland P, Hales C, Newsholme E. The glucose fatty-acid cycle. Its role in insulin sensitivity and the metabolic disturbances of diabetes mellitus. Lancet. 1963;1:785-9.
23. Boden G, Jadali F, White J, Liang Y, Mozzoli M, Chen X, et al. Effects of fat on insulin-stimulated carbohydrate metabolism in normal men. J Clin Invest. 1991;88:960-6.
24. Roden M, Price TB, Perseghin G, Petersen KF, Rothman DL Cline GW, et al. Mechanism of free fatty acid-induced insulin resistance in humans. J Clin Invest. 1996;97:2859-65.
25. DeFronzo R, Simonson D, Ferrannini E. Hepatic and peripheral insulin resistance: a common feature of type 2 (non-insulin-dependent) and type 1 (insulin-dependent) diabetes mellitus. Diabetologia. 1982;23:313-9.
26. Jeng CY, Sheu WH, Fuh MM, Chen YD, Reaven GM. Relationship between hepatic glucose production and fasting glucose concentration in patients with NIDDM. Diabetes. 1994;43:1440-4.
27. Kolterman OG, Gray RS, Griffin J, Burstein P, Insel J, Scarlett JA, et al. Receptor and postreceptor defects contribute to the insulin resistance in non-insulin-dependent diabetes mellitus. J Clin Invest. 1981;68:957-69.
28. Chen YD, Swislocki AL, Jeng CY, Juang JH, Reaven GM. Effect of time on measurement of hepatic glucose production. J Clin Endocrinol Metab. 1988;67:1084-8.
29. Hother-Nielsen O, Beck-Nielsen H. On the determination of basal glucose production rate in patients with type 2 (non-insulin-dependent) diabetes mellitus using primed-continuous 3-3H-glucose infusion. Diabetologia. 1990;33: 603-10.
30. Tominaga M, Igarashi M, Daimon M, Eguchi H, Matsumoto M, Sekikawa A, et al. Thiazolidinediones (AD-4833 and CS-045) improve hepatic insulin resistance in streptozotocin-induced diabetic rats. Endocr J. 1993; 40:343-9.
31. Lee MK, Miles PD, Khoursheed M, Gao KM, Moossa A, Olefsky JM. Metabolic effects of troglitazone on fructose-induced insulin resistance in the rat. Diabetes. 1994;43:1435-9.
32. Fujiwara T, Okuno A, Yoshioka S, Horikoshi H. Suppression of hepatic gluconeogenesis in long-term troglitazone treated diabetic KK and C57BL/ KsJ-db/db mice. Metabolism. 1995;44:486-90.
33. Inoue I, Takahashi K, Katayama S, Harada Y, Negishi K, Itabashi A, et al. Effect of troglitazone (CS-045) and bezafibrate on glucose tolerance, liver glycogen synthase activity, and B-oxidation in fructose-fed rats. Metabolism. 1995;44:1626-30.
34. Bogardus C, Lillioja S, Howard BV, Reaven G, Mott D. Relationship between insulin secretion, insulin action, and fasting plasma glucose concentration in nondiabetic and noninsulin-dependent diabetic subjects. J Clin Invest. 1984;74:1238-46.
35. Ferrannini E, Barrett EJ, Bevilaqua S, DeFronzo RA. Effect of fatty acids on glucose production and utilization in man. J Clin Invest. 1983;72:1737-47.
36. Rossetti L, Shulman GI, Zawalich W, DeFronzo RA. Effect of chronic hyperglycemia on in vivo insulin secretion in partially pancreatectomized rats. J Clin Invest. 1987;80:1037-44.
37. Bowen L, Stein PP, Stevenson R, Shulman GI. The effect of CP-68,772, a thiazolidinedione derivative, on insulin sensitivity in lean and obese Zucker rats. Metabolism. 1991;40:1025-30.
38. Kazumi T, Hirano T, Odaka H, Ebara T, Amano N, Hozumi T, et al. VLDL triglyceride kinetics in Wistar fatty rats, an animal model of NIDDM: effects of dietary fructose alone or in combination with pioglitazone. Diabetes. 1996;45:806-11.